Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
Abstract
Since the 1960s, hepatitis B virus surface antigen (HBsAg) has been the hallmark of HBV infection with concentrations reaching several hundred micrograms per millilitre.2 Recently, studies with newly available automated quantitative assays have shown that serum HBsAg levels vary significantly during the different phases of chronic HBV infection and are inversely correlated with the immune control of HBV: the higher control, the lower HBsAg level.3–6 These findings are consistent with the hypothesis that serum levels of HBsAg reflect the complex interplay between virus and immune system and provide complementary information to viral load as measured using HBV DNA levels. In fact, serum HBsAg levels result not only from virions (42 nm, Dane particles) but mainly from non-infectious HBsAg particles (20 nm diameter filaments of variable length and 20–22 nm spheres) which do not contain viral nucleic acids and exceed virions by a factor ranging between 102 and 105. The ratios between defective HBsAg particles and virions are not stable, but change over time. Filaments and spherical particles are produced in large excess in highly viraemic hepatitis B ‘e’ antigen (HBeAg)-positive carriers. While filaments decline in parallel with virions, spherical particles remain in moderate excess in low viraemic HBeAg-negative carriers.7 8 Thus, HBsAg production varies both quantitatively and qualitatively over time and appears to be dynamically regulated during different phases of the infection. HBsAg derives mainly from the intrahepatic viral minichromosome (cccDNA) by translation of specific RNAs that are distinct from pregenomic RNA, and HBsAg synthesis follows a pathway that is distinct from …Keywords
This publication has 43 references indexed in Scilit:
- Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels†Hepatology, 2010
- Toward Small Animal Models for the Study of Human Hepatitis VirusesHepatology, 2010
- Serum Hepatitis B Surface Antigen and Hepatitis B E Antigen Titers: Disease Phase Influences Correlation With Viral Load and Intrahepatic Hepatitis B Virus MarkersHepatology, 2010
- Evaluation of the patient with hepatitis B #Hepatology, 2009
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †Hepatology, 2009
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #Hepatology, 2009
- HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis BHepatology, 2008
- Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens†‡Hepatology, 2006
- Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis BHepatology, 2006
- Export of intracellular HBsAg in chronic hepatitis B virus infection is related to viral replication†Hepatology, 1991